ESR1 and neoplasm: This benefit from BPs in postmenopausal women was independent of the type of BP, estrogen receptor (ER) expression, lymph node status, tumor grade, or concomitant chemotherapy.47 However, BPs had no significant influence on dissemination to other organs, DFS or OS in DTC– patients.27 These clinical data indicate that bone marrow DTC clearance by BP treatment reduces the risk of extraosseous metastasis.